| 1 |
31641009 | Numerical Analysis of Time-Dependent Inhibition by MDMA. | 2020 Jan |
2 |
| 2 |
32228243 | MDMA interactions with pharmaceuticals and drugs of abuse. | 2020 May |
2 |
| 3 |
30070095 | Assessment of CYP2D6 re-activation after inhibitory effect of MDMA using tramadol as a probe. | 2018 Sep 25 |
1 |
| 4 |
30114388 | Kinetic mechanism of time-dependent inhibition of CYP2D6 by 3,4-methylenedioxymethamphetamine (MDMA): Functional heterogeneity of the enzyme and the reversibility of its inactivation. | 2018 Oct |
8 |
| 5 |
28904078 | Toward a systems approach to the human cytochrome P450 ensemble: interactions between CYP2D6 and CYP2E1 and their functional consequences. | 2017 Oct 10 |
2 |
| 6 |
26967321 | Impact of Cytochrome P450 2D6 Function on the Chiral Blood Plasma Pharmacokinetics of 3,4-Methylenedioxymethamphetamine (MDMA) and Its Phase I and II Metabolites in Humans. | 2016 |
3 |
| 7 |
27253829 | CYP2D6 function moderates the pharmacokinetics and pharmacodynamics of 3,4-methylene-dioxymethamphetamine in a controlled study in healthy individuals. | 2016 Aug |
5 |
| 8 |
27636207 | A Case of 3,4-Dimethoxyamphetamine (3,4-DMA) and 3,4-Methylenedioxymethamphetamine (MDMA) Toxicity with Possible Metabolic Interaction. | 2016 Nov-Dec |
1 |
| 9 |
25998998 | CYP2D6 genetic polymorphisms and their relevance for poisoning due to amfetamines, opioid analgesics and antidepressants. | 2015 Jul |
4 |
| 10 |
22713531 | Serotonin syndrome, disseminated intravascular coagulation, and hepatitis after a single ingestion of MDMA in an Asian woman. | 2014 Jul-Aug |
1 |
| 11 |
22211929 | Interaction of 3,4-methylenedioxymethamphetamine and methamphetamine during metabolism by in vitro human metabolic enzymes and in rats. | 2012 Jul |
2 |
| 12 |
22303032 | Ecstasy (MDMA)-induced hyponatraemia is associated with genetic variants in CYP2D6 and COMT. | 2012 Mar |
6 |
| 13 |
22673010 | Changes in CYP1A2 activity in humans after 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) administration using caffeine as a probe drug. | 2012 |
2 |
| 14 |
23030234 | Pharmacokinetics and pharmacodynamics of 3,4-methylenedioxymethamphetamine (MDMA): interindividual differences due to polymorphisms and drug-drug interactions. | 2012 Nov |
1 |
| 15 |
23112822 | Clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"): the influence of gender and genetics (CYP2D6, COMT, 5-HTT). | 2012 |
6 |
| 16 |
21456632 | Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans. | 2011 May |
6 |
| 17 |
20388857 | Differential roles of phase I and phase II enzymes in 3,4-methylendioxymethamphetamine-induced cytotoxicity. | 2010 Jul |
4 |
| 18 |
18725511 | The role of human hepatic cytochrome P450 isozymes in the metabolism of racemic 3,4-methylenedioxy-methamphetamine and its enantiomers. | 2008 Nov |
3 |
| 19 |
18794647 | The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans. | 2008 Oct |
3 |
| 20 |
17387004 | Kinetics of the time-dependent inactivation of CYP2D6 in cryopreserved human hepatocytes by methylenedioxymethamphetamine (MDMA). | 2007 May |
4 |
| 21 |
17598095 | An in vitro approach to potential methadone metabolic-inhibition interactions. | 2007 Sep |
1 |
| 22 |
17826363 | Cytochrome P450 bio-affinity detection coupled to gradient HPLC: on-line screening of affinities to cytochrome P4501A2 and 2D6. | 2007 Oct 15 |
1 |
| 23 |
17890444 | Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: pharmacological effects and pharmacokinetics. | 2007 Dec |
2 |
| 24 |
16478752 | The impact of experimental design on assessing mechanism-based inactivation of CYP2D6 by MDMA (Ecstasy). | 2006 Nov |
7 |
| 25 |
16563352 | Binding of bufuralol, dextromethorphan, and 3,4-methylenedioxymethylamphetamine to wild-type and F120A mutant cytochrome P450 2D6 studied by resonance Raman spectroscopy. | 2006 May 12 |
8 |
| 26 |
16714321 | Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA. | 2006 Nov |
6 |
| 27 |
17047487 | Influence of CYP2D6 polymorphism on 3,4-methylenedioxymethamphetamine ('Ecstasy') cytotoxicity. | 2006 Nov |
9 |
| 28 |
15910012 | Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probe. | 2005 |
4 |
| 29 |
16041599 | MDMA (ecstasy) pharmacokinetics in a CYP2D6 poor metaboliser and in nine CYP2D6 extensive metabolisers. | 2005 Aug |
1 |
| 30 |
16269134 | Role of the conserved threonine 309 in mechanism of oxidation by cytochrome P450 2D6. | 2005 Dec 16 |
1 |
| 31 |
15498516 | Influence of phenylalanine 120 on cytochrome P450 2D6 catalytic selectivity and regiospecificity: crucial role in 7-methoxy-4-(aminomethyl)-coumarin metabolism. | 2004 Dec 1 |
2 |
| 32 |
12006905 | Designer drugs that are potent inhibitors of CYP2D6. | 2002 Jun |
1 |
| 33 |
12110370 | Reduced (+/-)-3,4-methylenedioxymethamphetamine ("Ecstasy") metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro. | 2002 Jun 15 |
10 |
| 34 |
10671903 | Non-linear pharmacokinetics of MDMA ('ecstasy') in humans. | 2000 Feb |
2 |
| 35 |
10494994 | Acute toxicity of 3,4-methylenedioxymethamphetamine (MDMA) in Sprague-Dawley and Dark Agouti rats. | 1999 Sep |
2 |
| 36 |
26734924 | MDMA toxicity: no evidence for a major influence of metabolic genotype at CYP2D6. | 1998 Jul |
1 |
| 37 |
9264312 | Interactions of amphetamine analogs with human liver CYP2D6. | 1997 Jun 1 |
3 |
| 38 |
9311621 | Oxidation of methamphetamine and methylenedioxymethamphetamine by CYP2D6. | 1997 Sep |
1 |
| 39 |
7909223 | The demethylenation of methylenedioxymethamphetamine ("ecstasy") by debrisoquine hydroxylase (CYP2D6). | 1994 Mar 29 |
2 |